Cvaid Medical Ltd. secured $4 million in a series A financing to further develop its mobile stroke diagnostic, monitoring and treatment platform. The Israeli Rad Biomed investment fund led the round with participation from Philips Ventures and Sanara Capital. As part of the financing, a representative from Philips will join the board. The smartphone-based system, Cvaid uses artificial intelligence to process and analyze video and voice recordings to identify and assess the severity of patients experiencing stroke, also called cerebrovascular accidents.
Collplant Biotechnologies Ltd. has signed a collaboration agreement with 3D bioprinting company Cellink AB for future commercial production of regenerative breast implants. Rehovot, Israel-based Collplant has developed prototypes of 3D bioprinted implants and is evaluating them in preclinical studies. The regenerative implants are designed to degrade over time and be replaced by new, naturally grown breast tissue. The technology aims to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer.
Israel and U.S.-based Rsip Vision Ltd. has released a new supporting technology for intraoperative video analysis. The company says its offering provides real-time and accurate anatomical measurements in surgical videos. This supports a variety of clinical use cases, such as bariatric surgery and small bowel resection.
Be careful who you’re doing business with. That’s the warning the U.S. Court of Appeals for the District of Columbia Circuit sent this week to multinational drug and device companies doing business in terrorist hot spots around the world. Reversing a lower court, the D.C. Circuit cleared the way Jan. 4 for 21 drug and device companies to potentially be held accountable for doing business with Jaysh al-Mahdi terrorists, operating through the Iraqi Ministry of Health, who injured or killed hundreds of U.S. troops and civilians in Iraq.
The need to develop advanced medical technologies is ever increasing, and one incubator is on a mission to identify the world’s most promising opportunities. In cooperation with partners including Israel Innovation Authority, Israeli incubator Medx Xelerator LP is expanding a portfolio of startups that are attacking some of health care’s biggest challenges.
Venus Medtech (Hangzhou) Inc. reported it has acquired 100% equity interest and corresponding equity in Cardiovalve Ltd. for $300 million. Or Yehuda, Israel-based Cardiovalve produces the Cardiovalve system, a transcatheter interventional replacement product for mitral or tricuspid regurgitation.
Israeli startup Ophthalmic Sciences Ltd. is targeting 2023 for regulatory clearance of its artificial intelligence (AI)-based contactless intraocular pressure (IOP) measuring device, IO Perfect. The technology, which combines AI visual analysis in a virtual reality headset, enables remote monitoring of glaucoma. The device is designed to be used at home, in eye clinics, emergency room departments, pharmacies and primary physician settings.
Restore Medical Ltd. is implanting the first patients with its Contraband technology for congestive heart failure (CHF). The minimally invasive, catheter-delivered implant is being assessed in patients with chronic left ventricular failure. The Or Yehuda, Israel-based startup is carrying out the trial at the ZNA medical center in Antwerp, Belgium, followed by the Kaplan medical center in Israel. The goal of the implant is to enable the right ventricle to strengthen the left ventricle and improve ejection fraction, reduce mitral regurgitation and restore a favorable ventricular geometry.
Ilex Medical Ltd. has injected $3.2 million into cell therapy company Kadimastem Ltd., as it prepares to list on the Nasdaq. As part of the investment, Ilex Medical was granted a total of 1,407,130 options (60% coverage) in two series, at exercise prices of $2.2 and $2.7 per share (up to 100% from the share price at the transaction). If exercised, it would increase the total investment to $6.7 million.
RSS
